ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
A multimodal MRI radiomics model for distinguishing borderline from malignant ovarian epithelial tumors.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo develop and validate a multimodal MRI radiomics machine learning model for differentiating borderline epithelial ovarian tumors (BEOTs) from malignant epithelial ovarian tumors (MEOTs).
methodsA total of 147 patients (72 with BEOTs and 75 with MEOTs) were retrospectively enrolled and randomly divided into training and test cohorts at a ratio of 7:3. Multivariate logistic regression identified independent clinical predictors. A radiomic model was built using multimodal MRI features, and a radiomic score (Rad‑score) was calculated. A combined model integrating clinical predictors with Rad‑score was developed. ROC curve analysis and decision curve analysis (DCA) assessed model performance. The SHAP method was used to interpret the radiomic model.
resultsHuman epididymis protein 4 (HE4) was an independent risk factor for MEOTs and was used to construct the clinical model. The radiomic model comprised 17 features, with Rad‑scores differing significantly between BEOT and MEOT patients (cutoff = 0.564). A combined model integrated HE4 and Rad-score. Both the radiomic and combined models outperformed the clinical model in the training cohort (AUC: 0.968/0.970 vs. 0.858) and the test cohort (0.914/0.920 vs. 0.711; all p < 0.05), with no significant difference between them. DCA confirmed their superior net benefit. SHAP analysis revealed core features and their biological implications.
conclusionsThe multimodal MRI radiomics model interpreted by SHAP offers good diagnostic performance for differentiating BEOTs from MEOTs. As a non‑invasive, interpretable tool, it holds promise for clinical translation by assisting individualized treatment decisions and reducing unnecessary surgery.
Indexed as
Identifiers
42310186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.